{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"TEVA","limit":50},"count":50,"signals":[{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"(MSA). In addition, Phase 3 programs for duvakitug (anti-TL1A) were initiated in October 2025 in both ulcerative colitis and Crohns disease, and by year-end 2025, we achieved the targeted initial enrollment levels across both the adult and pediatric populations in the Phase 3 trial of DARIs (Dual- action Asthma Rescue Inhaler); | | |  |  |  On the third pillar, sustaining our generic medicines powerh","filed_date":"2026-03-31","accession":"0001193125-26-134756","full_text":"https://origin.rootz.global/static/filing/0001193125-26-134756.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"growth_inflection","strength":100,"match_count":15,"context":"Pivot to Growth strategy, Accelerate Growth:  |  |  |  We delivered strong performance on our key innovative products, mainly AUSTEDO, AJOVY, and UZEDY, even raising our guidance for AUSTEDO. AUSTEDO revenue grew 34%, UZEDY revenue grew 63% and AJOVY revenue grew 30% in local currencies compared to 2024. | | |  |  |  We continued to drive progress in the development of certain key pipeline assets, including filin","filed_date":"2026-03-31","accession":"0001193125-26-134756","full_text":"https://origin.rootz.global/static/filing/0001193125-26-134756.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"iewed and discussed the assessment for 2025.The HR and Compensation Committee determined that our compensation program, policies and practices do not create risks that are reasonably likely to have a material adverse effect on Teva.  69|Teva Pharmaceutical Industries Ltd. 2026 Proxy Statement  [Table of Contents](#toc) EXECUTIVE COMPENSATION  Compensation Policy Requirements  Pursuant to the Israeli Companies Law, arran","filed_date":"2026-03-31","accession":"0001193125-26-134756","full_text":"https://origin.rootz.global/static/filing/0001193125-26-134756.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":24,"context":"targets, including meeting compliance and ethics training targets |  |  |  |  Key Performance Accomplishments Entered license agreement with Prestige Biopharma for Tuznue commercialization in Europe Entered into strategic partnership with Fosun Pharma to develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology Met transformation and leadership targets Met sustainability targets, including: achieved >99% compliance and et","filed_date":"2026-03-31","accession":"0001193125-26-134756","full_text":"https://origin.rootz.global/static/filing/0001193125-26-134756.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":100,"match_count":13,"context":"e purchasing organizations, mail order distributors and hospitals. These customers have undergone significant consolidation and formed various commercial alliances, which may continue to increase the pricing pressures that we face in the United States. The presence of large buying groups, and the prevalence and influence of managed care organizations and similar institutions, have increased pressure on price, as","filed_date":"2026-02-03","accession":"0001193125-26-034532","full_text":"https://origin.rootz.global/static/filing/0001193125-26-034532.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":129,"context":"deny or revoke approvals of marketing applications and the power to halt the operations of non-complying manufacturers. Any failure to comply with applicable FDA policies and regulations could have a material adverse effect on our operations.  FDA approval is required before any new drug (including generic versions of previously approved drugs) may be marketed, including new strengths, dosage forms and formulations of p","filed_date":"2026-02-03","accession":"0001193125-26-034532","full_text":"https://origin.rootz.global/static/filing/0001193125-26-034532.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"forfeited compensation opportunities at his prior employer and to incentivize him to join the Company as CEO, Mr.Francis received a sign-on cash award of $5million, which is being paid in three installments. The second installment, equal to $1,500,000, was paid in 2024 and is reflected in the Bonus column of the Summary Compensation Table.  72|Teva Pharmaceutical Industries Ltd. 2025 Proxy Statement","filed_date":"2025-04-09","accession":"0001193125-25-076829","full_text":"https://origin.rootz.global/static/filing/0001193125-25-076829.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"iewed and discussed the assessment for 2024.The HR and Compensation Committee determined that our compensation program, policies and practices do not create risks that are reasonably likely to have a material adverse effect on Teva.  Compensation Policy Requirements  Pursuant to the Israeli Companies Law, arrangements between Teva and its Office Holders must generally be consistent with the Compensation Policy. However,","filed_date":"2025-04-09","accession":"0001193125-25-076829","full_text":"https://origin.rootz.global/static/filing/0001193125-25-076829.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":21,"context":"at the same time and format. By Order of the Board of Directors,  Dov Bergwerk Senior Vice President, Company Secretary April9, 2025 Agenda 1.Election of Directors; 2.Advisory Vote on Compensation of Named Executive Officers; 3.Approval of Tevas Amended Compensation Policy; 4.Approval of an Amendment to the Terms of Office and Employment of Tevas President and Chief Executive Officer; 5.Approval of an Amendment to Direc","filed_date":"2025-04-09","accession":"0001193125-25-076829","full_text":"https://origin.rootz.global/static/filing/0001193125-25-076829.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":100,"match_count":14,"context":"e purchasing organizations, mail order distributors and hospitals. These customers have undergone significant consolidation and formed various commercial alliances, which may continue to increase the pricing pressures that we face in the United States. The presence of large buying groups, and the prevalence and influence of managed care organizations and similar institutions, have increased pressure on price, as","filed_date":"2025-02-05","accession":"0001193125-25-020826","full_text":"https://origin.rootz.global/static/filing/0001193125-25-020826.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":124,"context":"deny or revoke approvals of marketing applications and the power to halt the operations of non-complying manufacturers. Any failure to comply with applicable FDA policies and regulations could have a material adverse effect on our operations.  FDA approval is required before any new drug (including generic versions of previously approved drugs) may be marketed, including new strengths, dosage forms and formulations of p","filed_date":"2025-02-05","accession":"0001193125-25-020826","full_text":"https://origin.rootz.global/static/filing/0001193125-25-020826.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"iewed and discussed the assessment for 2023.The HR and Compensation Committee determined that our compensation program, policies and practices do not create risks that are reasonably likely to have a material adverse effect on Teva.  Compensation Policy Requirements  Pursuant to the Israeli Companies Law, arrangements between Teva and its Office Holders must generally be consistent with the Compensation Policy. However,","filed_date":"2024-04-16","accession":"0001193125-24-097745","full_text":"https://origin.rootz.global/static/filing/0001193125-24-097745.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":24,"context":"| |  | |  Executive Compensation |  |  |  39 |  | | |  | |  HR and Compensation Committee Interlocks and Insider Participation |  |  |  97 |  | | |  | |  Proposal 2: Advisory Vote on Compensation of Named Executive Officers |  |  |  98 |  | | |  | |  Proposal 3: Advisory Vote on Frequency of Advisory Vote on Compensation of Named Executive Officers |  |  |  99 |  | | |  | |  Proposal 4: Appointment of Independent Regis","filed_date":"2024-04-16","accession":"0001193125-24-097745","full_text":"https://origin.rootz.global/static/filing/0001193125-24-097745.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":118,"context":"deny or revoke approvals of marketing applications and the power to halt the operations of non-complying manufacturers. Any failure to comply with applicable FDA policies and regulations could have a material adverse effect on our operations.  FDA approval is required before any new drug (including generic versions of previously approved drugs) may be marketed, including new strengths, dosage forms and formulations of p","filed_date":"2024-02-12","accession":"0001193125-24-031005","full_text":"https://origin.rootz.global/static/filing/0001193125-24-031005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":29,"context":"iewed and discussed the assessment for 2022.The HR and Compensation Committee determined that our compensation program, policies and practices do not create risks that are reasonably likely to have a material adverse effect on Teva.  Compensation Policy Requirements  Pursuant to the Israeli Companies Law, arrangements between Teva and its Office Holders must generally be consistent with the Compensation Policy. However,","filed_date":"2023-04-19","accession":"0001193125-23-106453","full_text":"https://origin.rootz.global/static/filing/0001193125-23-106453.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":24,"context":"debt and optimizing our manufacturing and supply chain, while investing for growth.  Leadership transition  Kre Schultz retired from the Company effective December31, 2022 and Richard D. Francis was appointed President and CEO and a member of the Board of Directors on January1, 2023. Under Kres leadership, the Company executed on a comprehensive restructuring plan, which significantly reduced our spending to allow us to fu","filed_date":"2023-04-19","accession":"0001193125-23-106453","full_text":"https://origin.rootz.global/static/filing/0001193125-23-106453.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":58,"context":"deny or revoke approvals of marketing applications and the power to halt the operations of non-complying manufacturers. Any failure to comply with applicable FDA policies and regulations could have a material adverse effect on our operations.  FDA approval is required before any new drug (including generic versions of previously approved drugs) may be marketed, including new strengths, dosage forms and formulations of p","filed_date":"2023-02-10","accession":"0001193125-23-031250","full_text":"https://origin.rootz.global/static/filing/0001193125-23-031250.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"ewed and discussed the assessment for 2021. The HR and Compensation Committee determined that our compensation program, policies and practices do not create risks that are reasonably likely to have a material adverse effect on Teva.  **Compensation Policy Requirements** Pursuant to the Israeli Companies Law, arrangements between Teva and its Office Holders must generally be consistent with the Compensation Policy. Howev","filed_date":"2022-04-13","accession":"0001193125-22-103714","full_text":"https://origin.rootz.global/static/filing/0001193125-22-103714.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":26,"context":"in, Roberto A. Mignone, Dr. Perry D. Nisen and Dr. Tal Zaks to serve until our 2025 annual meeting of shareholders. Proposal 2: To approve, on a non-binding advisory basis, the compensation for Tevas named executive officers.  Proposal 3: To approve Tevas Compensation Policy with respect to the terms of office and employment of Tevas Executive Officers and Directors, substantially in the form attached as Appendix A to t","filed_date":"2022-04-13","accession":"0001193125-22-103714","full_text":"https://origin.rootz.global/static/filing/0001193125-22-103714.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":46,"context":"deny or revoke approvals of marketing applications and the power to halt the operations of non-complying manufacturers. Any failure to comply with applicable FDA policies and regulations could have a material adverse effect on our operations.  FDA approval is required before any new drug (including generic versions of previously approved drugs) may be marketed, including new strengths, dosage forms and formulations of p","filed_date":"2022-02-09","accession":"0001193125-22-032667","full_text":"https://origin.rootz.global/static/filing/0001193125-22-032667.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ewed and discussed the assessment for 2020. The HR and Compensation Committee determined that our compensation program, policies and practices do not create risks that are reasonably likely to have a material adverse effect on Teva.  **Compensation Policy Requirements** Pursuant to the Israeli Companies Law, arrangements between Teva and its Office Holders must generally be consistent with the Compensation Policy. Howev","filed_date":"2021-04-21","accession":"0001193125-21-124697","full_text":"https://origin.rootz.global/static/filing/0001193125-21-124697.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":22,"context":"|  |  |  |  We launched our Digihaler portfolio, the first and only digital, breath-actuated inhalers with built-in sensors that track inhaler events and measure inspiratory flow. | | |  |  |  |  We announced a strategic partnership with Alvotech for the exclusive commercialization of five biosimilar product candidates in the U.S. | | |  |  |  |  We renewed our Environmental, Social, and Governance (ESG) strategy, published our","filed_date":"2021-04-21","accession":"0001193125-21-124697","full_text":"https://origin.rootz.global/static/filing/0001193125-21-124697.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":14,"context":"uirements.  13  [Table of Contents](#toc) Between 2017 and 2019, we closed or divested a significant number of manufacturing plants in the United States, Europe, Israel and Japan in connection with a restructuring plan. We are continuing our ongoing efforts to consolidate our manufacturing and supply network.  Raw Materials for Pharmaceutical Production  In general, we purchase our raw materials and supplies requir","filed_date":"2021-02-10","accession":"0001193125-21-036239","full_text":"https://origin.rootz.global/static/filing/0001193125-21-036239.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":42,"context":"eny or revoke approvals of marketing applications and the power to halt the operations of  non-complying manufacturers. Any failure to comply with applicable FDA policies and regulations could have a material adverse effect on our operations.  FDA approval is required before any new drug (including generic versions of previously approved drugs) may be marketed, including new strengths, dosage forms and formulations of p","filed_date":"2021-02-10","accession":"0001193125-21-036239","full_text":"https://origin.rootz.global/static/filing/0001193125-21-036239.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":34,"context":"chel Halfon, Nechemia (Chemi) J. Peres and Janet S. Vergis to serve until our 2023 annual meeting of shareholders.  Proposal 2: To approve, on a non-binding advisory basis, the compensation for Tevas named executive officers. Proposal 3: To approve Tevas 2020 Long-Term Equity-Based Incentive Plan, substantially in the form attached as Appendix A to this Proxy Statement.  Proposal 4: To approve an amendment to the terms","filed_date":"2020-04-22","accession":"0001193125-20-114316","full_text":"https://origin.rootz.global/static/filing/0001193125-20-114316.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":58,"context":"credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; | | |  |  |  our business and operations in general, including: implementation of our restructuring plan announced in December 2017; our ability to attract, hire and retain highly skilled personnel; our ability to develop and commercialize additional pharmaceutical products; compliance with anti-corrupt","filed_date":"2020-02-21","accession":"0001193125-20-044221","full_text":"https://origin.rootz.global/static/filing/0001193125-20-044221.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":45,"context":"eny or revoke approvals of marketing applications and the power to halt the operations of  non-complying manufacturers. Any failure to comply with applicable FDA policies and regulations could have a material adverse effect on our operations. FDA approval is required before any new drug (including generic versions of previously approved drugs) may be marketed, including new strengths, dosage forms and formulations of pr","filed_date":"2020-02-21","accession":"0001193125-20-044221","full_text":"https://origin.rootz.global/static/filing/0001193125-20-044221.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":14,"context":"n-GAAP EPS is expected to be $2.30 - $2.55 - Free cash flow is expected to be $1.8 - $2.2 billion In 2019, we made great strides towards positioning Teva for renewed growth by completing our two-year restructuring plan, reducing our cost base by more than $3 billion, and reducing our net debt by more than $9 billion, all while maintaining our global leadership in generics, serving around 200 million patients every","filed_date":"2020-02-12","accession":"0001157523-20-000188","full_text":"https://origin.rootz.global/static/filing/0001157523-20-000188.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":21,"context":"gs; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; | | |  |  |  our business and operations in general, including: failure to effectively execute our restructuring plan announced in December 2017; uncertainties related to, and failure to achieve, the potential benefits and success of our senior management team and organizational structure, including changes to our s","filed_date":"2019-11-07","accession":"0001193125-19-287265","full_text":"https://origin.rootz.global/static/filing/0001193125-19-287265.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":22,"context":"gs; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; | | |  |  |  our business and operations in general, including: failure to effectively execute our restructuring plan announced in December 2017; uncertainties related to, and failure to achieve, the potential benefits and success of our senior management team and organizational structure; harm to our pipeline of fu","filed_date":"2019-08-07","accession":"0001193125-19-215317","full_text":"https://origin.rootz.global/static/filing/0001193125-19-215317.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":13,"context":"Second Quarter 2019 Financial Results - Revenues of $4.3 billion - GAAP diluted loss per share of $0.63 - Non-GAAP diluted EPS of $0.60 - Spend base reduction of $2.7 billion since initiation of the restructuring plan in 2018; on-track to achieve $3.0 billion by the end of 2019 - Full year 2019 revenues and EPS guidance reaffirmed** JERUSALEM--(BUSINESS WIRE)--August 7, 2019--Teva Pharmaceutical Industries Ltd. (N","filed_date":"2019-08-07","accession":"0001157523-19-001739","full_text":"https://origin.rootz.global/static/filing/0001157523-19-001739.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":19,"context":"and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; | | |  |  |  |  our business and operations in general, including: failure to effectively execute our restructuring plan announced in December 2017; uncertainties related to, and failure to achieve, the potential benefits and success of our senior management team and organizational structure; harm to our pipeline of fu","filed_date":"2019-05-02","accession":"0001193125-19-134970","full_text":"https://origin.rootz.global/static/filing/0001193125-19-134970.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":16,"context":"|  |  Dr. Sol J. Barer |  |  |  |  |  This year we achieved some important milestones in our journey to stabilize our business and build a solid future for Teva. In December 2017, we began a two-year restructuring plan to significantly reduce our cost base, unify and simplify the organization, and improve business performance, profitability, cash flow generation and productivity. The plan was chiefly designed to ad","filed_date":"2019-04-16","accession":"0001193125-19-107826","full_text":"https://origin.rootz.global/static/filing/0001193125-19-107826.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":31,"context":"A. Mignone and Dr. Perry D. Nisen to serve on the Board of Directors until our 2022 annual meeting of shareholders. Proposal 2: To approve, on a non-binding advisory basis, the compensation for Tevas named executive officers.  Proposal 3: To approve an amended Compensation Policy with respect to the terms of office and employment of Tevas Executive Officers and Directors, substantially in the form attached as Appendix A","filed_date":"2019-04-16","accession":"0001193125-19-107826","full_text":"https://origin.rootz.global/static/filing/0001193125-19-107826.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":19,"context":"diary Borrowers.  **Loans** shall mean, as the context may require, a Revolving Loan or any Swingline Loan made by the Lenders under any Tranche to any of the Borrowers pursuant to this Agreement.  **Material Adverse Effect** means any event or circumstance which:  |  |  (a) |  is materially adverse to: | | |  |  (i) |  the business, operations or financial condition of the Loan Parties and their Subsidiaries, taken as","filed_date":"2019-04-10","accession":"0001193125-19-102327","full_text":"https://origin.rootz.global/static/filing/0001193125-19-102327.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":60,"context":"and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; | | |  |  |  |  our business and operations in general, including: failure to effectively execute our restructuring plan announced in December 2017; uncertainties related to, and failure to achieve, the potential benefits and success of our senior management team and organizational structure; harm to our pipeline of fu","filed_date":"2019-02-19","accession":"0001193125-19-043564","full_text":"https://origin.rootz.global/static/filing/0001193125-19-043564.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"deny or revoke approvals of marketing applications and the power to halt the operations of non-complying manufacturers. Any failure to comply with applicable FDA policies and regulations could have a material adverse effect on our operations.  FDA approval is required before any new drug (including generic versions of previously approved drugs) may be marketed, including new strengths, dosage forms and formulations of p","filed_date":"2019-02-19","accession":"0001193125-19-043564","full_text":"https://origin.rootz.global/static/filing/0001193125-19-043564.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":9,"context":"tember 2017. TD is a debilitating, often irreversible movement disorder caused by certain medications used to treat mental health or gastrointestinal conditions. | | |  |  |  |  In September 2017, we entered into a partnership agreement with Nuvelution Pharma, Inc (Nuvelution) for the development of AUSTEDO for the treatment of Tourette syndrome in pediatric patients in the United States. | | 7  [Table of Contents](#toc) |  |  |  |","filed_date":"2019-02-19","accession":"0001193125-19-043564","full_text":"https://origin.rootz.global/static/filing/0001193125-19-043564.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":25,"context":"and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; | | |  |  |  |  our business and operations in general, including: failure to effectively execute our restructuring plan announced in December 2017; uncertainties related to, and failure to achieve, the potential benefits and success of our new senior management team and organizational structure; harm to our pipeline o","filed_date":"2018-11-01","accession":"0001193125-18-315734","full_text":"https://origin.rootz.global/static/filing/0001193125-18-315734.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":14,"context":"the preventive treatment of migraine and we are seeing very good signs of a successful launch. We continue to see strong growth for AUSTEDO, while COPAXONE continues to maintain its market share. Our restructuring plan has already resulted in a significant cost reduction of $1.8 billion in the first nine months of the year and we are on track to achieve a reduction of $3.0 billion by the end of 2019, while continui","filed_date":"2018-11-01","accession":"0001157523-18-002246","full_text":"https://origin.rootz.global/static/filing/0001157523-18-002246.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":27,"context":"and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; | | |  |  |  |  our business and operations in general, including: failure to effectively execute our restructuring plan announced in December 2017; uncertainties related to, and failure to achieve, the potential benefits and success of our new senior management team and organizational structure; harm to our pipeline o","filed_date":"2018-08-02","accession":"0001193125-18-236536","full_text":"https://origin.rootz.global/static/filing/0001193125-18-236536.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":22,"context":"and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; | | |  |  |  |  our business and operations in general, including: failure to effectively execute our restructuring plan announced in December 2017; uncertainties related to, and failure to achieve, the potential benefits and success of our new senior management team and organizational structure; harm to our pipeline o","filed_date":"2018-05-03","accession":"0001193125-18-150803","full_text":"https://origin.rootz.global/static/filing/0001193125-18-150803.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":26,"context":"h a grant date fair value of $5 million (as determined based on the closing price of Tevas shares on the date prior to the announcement of Mr. Schultzs hire), which will vest and settle in equal installments on the third, fourth and fifth anniversaries of the employment commencement date (the **Effective Date**); and (ii) two sign-on performance share unit awards, each with a target grant date fair v","filed_date":"2018-04-25","accession":"0001193125-18-130745","full_text":"https://origin.rootz.global/static/filing/0001193125-18-130745.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":55,"context":"ld M. Lieberman and Prof. Ronit Satchi-Fainaro as directors to serve until our 2021 annual meeting of shareholders. Proposal 2: To approve, on a non-binding advisory basis, the compensation for Tevas named executive officers.  Proposal 3: To recommend, on a non-binding advisory basis, to hold a non-binding, advisory vote to approve the compensation for Tevas named executive officers every one, two or three years.  Propo","filed_date":"2018-04-25","accession":"0001193125-18-130745","full_text":"https://origin.rootz.global/static/filing/0001193125-18-130745.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":57,"context":"to raise debt or borrow funds in amounts or on terms that are favorable to us; | | |  |  |  |  our business and operations in general, including: failure to effectively execute the recently announced restructuring plan; uncertainties related to, and failure to achieve, the potential benefits and success of our new senior management team and organizational structure; harm to our pipeline of future products due to th","filed_date":"2018-02-12","accession":"0001193125-18-039076","full_text":"https://origin.rootz.global/static/filing/0001193125-18-039076.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"ng through, among other things, stronger prevention and wellness measures, increased access to primary care, changes in healthcare delivery systems and the creation of health insurance exchanges. Enrollment in the health insurance exchanges began in October 2013. However, the individual mandate was just repealed by Congress in the tax reform bill that was signed into law in December 2017. The Joint C","filed_date":"2018-02-12","accession":"0001193125-18-039076","full_text":"https://origin.rootz.global/static/filing/0001193125-18-039076.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":100,"match_count":13,"context":"its of generics through partnerships and digital marketing programs.  During 2017 our generics business in the United States was negatively impacted by certain developments, including: (i) additional pricing pressure as a result of customer consolidation into larger buying groups capable of extracting greater price reductions, (ii) an accelerated FDA approval process for generic versions of off-patent medicines,","filed_date":"2018-02-12","accession":"0001193125-18-039076","full_text":"https://origin.rootz.global/static/filing/0001193125-18-039076.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"deny or revoke approvals of marketing applications and the power to halt the operations of non-complying manufacturers. Any failure to comply with applicable FDA policies and regulations could have a material adverse effect on our operations.  FDA approval is required before any new drug (including generic versions of previously approved drugs) may be marketed, including new strengths, dosage forms and formulations of p","filed_date":"2018-02-12","accession":"0001193125-18-039076","full_text":"https://origin.rootz.global/static/filing/0001193125-18-039076.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":45,"context":"ted the sale of PARAGARD, a copper releasing intrauterine contraceptive manufactured and sold in the United States, to CooperSurgical for $1.1 billion in cash.  **AUSTEDO** On September, 19, 2017, we entered into a partnership agreement with Nuvelution Pharma, Inc. (Nuvelution) for development of AUSTEDO for the treatment of Tourette syndrome in pediatric patients in the United States. Nuvelution will fund and manage phase 3 clinica","filed_date":"2018-02-12","accession":"0001193125-18-039076","full_text":"https://origin.rootz.global/static/filing/0001193125-18-039076.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TEVA","company":"TEVA PHARMACEUTICAL INDUSTRIES LTD","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"hise as a percentage of Copaxone revenues was 81%, 77% and 75% in 2016, 2015 and 2014, respectively. Accordingly, the failure to achieve and maintain our objectives for Copaxone 40 mg/mL would have a material adverse effect on our financial results and cash flow.  Certain of our other leading specialty medicines also face patent challenges and impending patent expirations. For example, a generic version of Azilect was l","filed_date":"2017-02-15","accession":"0001193125-17-045463","full_text":"https://origin.rootz.global/static/filing/0001193125-17-045463.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"c3e9a6dee0bf92bf2e613b4d2891c7c9a4e055be79abd0ef59433200343edde6","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"51571bae54a85a8451092fbb71dae07cfa838ad8e63cd7be30d6a2a5ece62a92","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":103,"hourly_limit":500,"remaining":397,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}